Satsuma Pharma surges; co announces results of clinical trial
16/06/2021 21:24
** Shares of Satsuma Pharmaceuticals Inc STSA.O surging 19% in
extended trade on Wed after the co announced positive results
from a phase 1 trail of STS101 nasal powder for migraines
** STSA said it found positive pharmacokinetic, tolerability
and safety results in the trial of STS101 at multiple dose
strengths urn:newsml:reuters.com:*:nNDLZTYnC
** Co said it was initiating summit phase 3 efficacy trial
focused on STS101 5.2 mg in acute treatment of migraine attacks
((noel.randewich@tr.com; (415) 677 2542, Twitter: @randewich;))
Recent news on Satsuma Pharmaceuticals
See all newsBrief: Satsuma Pharmaceuticals Announces FDA Acceptance Of 505(B)(2) NDA For Sts101, A Novel And Investigational Dihydroergotamine Nasal Powder Product For The Acute Treatment Of Migraine
Commencement Of Tender Offer For Satsuma Pharmaceuticals, Inc In U.S.
Brief: Satsuma Pharmaceuticals Says Received Letter Notifying Co Regained Compliance With Nasdaq
U.S. STOCKS ON THE MOVE-Alphabet Inc, BlackRock, Moderna
Satsuma Pharma soars on buyout deal from Japan's Shin Nippon